209 related articles for article (PubMed ID: 30569379)
1. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
2. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
3. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
4. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
[TBL] [Abstract][Full Text] [Related]
5. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
Luo YR; Chakraborty I; Lazar-Molnar E; Wu AHB; Lynch KL
Clin Chem; 2020 Oct; 66(10):1319-1328. PubMed ID: 32918468
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
7. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Marín-Jiménez I; Menchén LA; López-Cauce B; López-Fernández LA; Lucendo AJ
J Pharm Biomed Anal; 2021 May; 198():114003. PubMed ID: 33714800
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
10. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.
Rubin DT; Naik S; Kondragunta V; Rao T; Jain A
Curr Med Res Opin; 2017 May; 33(5):837-843. PubMed ID: 28145781
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
[TBL] [Abstract][Full Text] [Related]
15. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.
El Amrani M; Bosman SM; Egas AC; Hack CE; Huitema ADR; van Maarseveen EM
Ther Drug Monit; 2019 Oct; 41(5):640-647. PubMed ID: 31584927
[TBL] [Abstract][Full Text] [Related]
17. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.
Toja-Camba FJ; García-Quintanilla L; Rodríguez-Martinez L; Tomine J; Cajade-Pascual F; Feitosa C; Zarra-Ferro I; Barreiro-De-Acosta M; González-López J; Mondelo-García C; Fernández-Ferreiro A
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004593
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations.
van Bezooijen JS; Koch BC; van Doorn MB; Prens EP; van Gelder T; Schreurs MW
Ther Drug Monit; 2016 Aug; 38(4):432-8. PubMed ID: 27120178
[TBL] [Abstract][Full Text] [Related]
20. Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.
Homann A; Röckendorf N; Kromminga A; Frey A; Platts-Mills TA; Jappe U
Theranostics; 2017; 7(19):4699-4709. PubMed ID: 29187897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
